Drug Profile
Research programme: bacteriophage therapeutics - Ferring Pharmaceuticals/Institut Pasteur
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals; Institute Pasteur
- Developer Ferring Pharmaceuticals; Institute Pasteur; Intralytix
- Class Bacteriophages
- Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Dysbiosis; Inflammatory bowel diseases
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in Switzerland
- 28 Feb 2021 No recent reports of development identified for research development in Dysbiosis in USA
- 15 Feb 2018 Preclinical trials in Inflammatory bowel disease in Switzerland (unspecified route)